Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

Myelodysplastic Syndromes

(2017) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

(2012) F. Thol et al.   BLOOD

Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis

(2012) H. Makishima et al.   BLOOD

Predicting survival of patients with hypocellular myelodysplastic syndrome

(2012) Wei-Gang Tong et al.   CANCER

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

(2011) K. Naqvi et al.   BLOOD

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

(2011) L. Malcovati et al.   BLOOD

Targeting Immune Dysregulation in Myelodysplastic Syndromes

(2011) Matthew J. Olnes   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA

(2010) Hui Yang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

(2010) Elias Jabbour et al.   CANCER

Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

(2010) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99

(2010) Jakob R. Passweg et al.   JOURNAL OF CLINICAL ONCOLOGY

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

(2009) R Garg et al.   LEUKEMIA

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

(2009) J X Zou et al.   LEUKEMIA

Myelodysplastic Syndromes

(2009) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

(2008) Victor Moyo et al.   ANNALS OF HEMATOLOGY

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

(2008) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

(2008) Mikkael A. Sekeres et al.   JNCI-Journal of the National Cancer Institute

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

(2007) S. Park et al.   BLOOD